These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28838265)

  • 41. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
    Chemama S; Bayar MA; Lanoy E; Ammari S; Stoclin A; Goéré D; Elias D; Raynard B; Antoun S
    Ann Surg Oncol; 2016 Nov; 23(12):3891-3898. PubMed ID: 27352205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome.
    Blaj S; Nedelcut S; Mayr M; Leebmann H; Leucuta D; Glockzin G; Piso P
    Langenbecks Arch Surg; 2019 Aug; 404(5):541-546. PubMed ID: 31352505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
    Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
    Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy.
    Younan R; Kusamura S; Baratti D; Cloutier AS; Deraco M
    J Surg Oncol; 2008 Sep; 98(4):253-7. PubMed ID: 18726887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies.
    Choudry MHA; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Dec; 25(13):3950-3959. PubMed ID: 30302637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Eng OS; Dumitra S; O'Leary M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Benjamin Paz I; Singh G; Lee B
    Ann Surg Oncol; 2017 Sep; 24(9):2707-2711. PubMed ID: 28560593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the Combination of Distal Pancreatectomy and Cytoreductive Surgery With HIPEC Reasonable?: Results of an International Multicenter Study.
    Schwarz L; Votanopoulos K; Morris D; Yonemura Y; Deraco M; Piso P; Moran B; Levine EA; Tuech JJ
    Ann Surg; 2016 Feb; 263(2):369-75. PubMed ID: 25915913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allogenic Blood Transfusion Is an Independent Predictor of Poorer Peri-operative Outcomes and Reduced Long-Term Survival after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Review of 936 Cases.
    Saxena A; Valle SJ; Liauw W; Morris DL
    J Gastrointest Surg; 2017 Aug; 21(8):1318-1327. PubMed ID: 28560703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infectious Complications after Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy.
    Arslan NC; Sokmen S; Avkan-Oguz V; Obuz F; Canda AE; Terzi C; Fuzun M
    Surg Infect (Larchmt); 2017; 18(2):157-163. PubMed ID: 27906610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-home Discharge and Prolonged Length of Stay After Cytoreductive Surgery and HIPEC.
    Burguete D; Mokdad AA; Augustine MM; Minter R; Mansour JC; Choti MA; Polanco PM
    J Surg Res; 2019 Jan; 233():360-367. PubMed ID: 30502272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Randle RW; Ahmed S; Levine EA; Fino NF; Swett KR; Stewart JH; Shen P; Votanopoulos KI
    J Surg Oncol; 2015 May; 111(6):740-5. PubMed ID: 25556634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC).
    Fisher SB; Rafeeq S; Hess K; Grotz TE; Mansfield P; Royal R; Badgwell B; Fleming J; Fournier K; Mann GN
    J Surg Oncol; 2018 Mar; 117(4):685-691. PubMed ID: 29193085
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
    Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
    Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An analysis of the morbidity associated with abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
    Parikh R; Shah S; Dhurandhar V; Alzahrani N; Fisher OM; Arrowaili A; Liauw W; Morris D
    Eur J Surg Oncol; 2019 Mar; 45(3):394-399. PubMed ID: 30638806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Shannon NB; Chia CS; Soo KC; Teo MCC
    Int J Hyperthermia; 2018 Aug; 34(5):595-600. PubMed ID: 28633580
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploring the trend in referrals for consideration of CRS and HIPEC to understand the attitudes of clinicians in the development of a national cancer centre programme in peritoneal disease.
    Wang W; Tan GHC; Skanthakumar T; Chia CS; Soo KC; Teo MCC
    Int J Hyperthermia; 2018 Aug; 34(5):551-558. PubMed ID: 28978237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.